QTREX Quantum Ltd. QTEX
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.45
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $289.0K | $0 | $0 | — | — | — | — | — |
| Cost of revenue | $287.0K | $0 | $0 | — | — | — | — | — |
| Gross profit | $2.0K | $0 | $0 | — | — | — | — | — |
| R&D | $7.5M | $6.3M | $7.3M | $8.2M | $4.1M | — | — | — |
| SG&A | $5.5M | $4.2M | $4.1M | $5.4M | $6.9M | — | — | — |
| Operating income | -$13.6M | -$11.3M | -$12.1M | -$14.9M | -$13.0M | $6.3M | $1.3M | — |
| Interest expense | — | — | $1.2M | — | — | — | — | — |
| Pre-tax income | -$13.2M | -$11.1M | -$11.3M | -$15.0M | -$17.2M | — | — | — |
| Income tax | $0 | $0 | $0 | — | — | — | — | — |
| Net income | -$13.2M | -$11.1M | -$11.3M | -$15.0M | -$17.2M | -$7.2M | -$4.6M | — |
| EPS, basic | -0.45 | -0.60 | -0.93 | -1.39 | -3.24 | — | — | — |
| EPS, diluted | -0.45 | -0.60 | -0.93 | -1.39 | -3.24 | — | — | — |
| Shares, diluted (wtd. avg.) | 29.6M | 18.5M | 12.1M | 10.8M | 5.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.2M | $5.1M | $5.0M | $6.8M | $23.9M | $541.0K | — | — |
| Short-term investments | — | $700.0K | $2.3M | $7.1M | — | — | — | — |
| Inventory | $735.0K | $444.0K | — | — | — | — | — | — |
| Total current assets | $4.4M | $6.8M | $7.8M | $14.5M | — | — | — | — |
| Property, plant and equipment | $452.0K | $499.0K | $506.0K | $411.0K | — | — | — | — |
| Total assets | $5.3M | $8.1M | $9.3M | $16.2M | $25.9M | $987.0K | — | — |
| Total current liabilities | $2.8M | $3.4M | $3.0M | $1.7M | — | — | — | — |
| Total equity | $2.3M | $4.3M | $5.7M | $13.6M | $23.7M | -$1.3M | -$4.6M | -$29.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.9M | -$9.4M | -$9.7M | -$9.2M | -$6.7M | — | — | — |
| Depreciation and amortisation | $150.0K | $171.0K | $111.0K | $54.0K | $25.0K | — | — | — |
| Stock-based compensation | $3.6M | $1.9M | $1.4M | $4.9M | $6.7M | — | — | — |
| Capital expenditure | $103.0K | $164.0K | $206.0K | $263.0K | $182.0K | — | — | — |
| Investing cash flow | $565.0K | $1.5M | $4.6M | -$7.4M | -$182.0K | — | — | — |
| Financing cash flow | $7.3M | $7.9M | $3.5M | — | $30.2M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001185185-26-001072.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $289.0K |
| Gross profit | — | — | — | — | — | $0 | $0 | $2.0K |
| Net income | — | -$4.6M | -$7.2M | -$17.2M | -$15.0M | -$11.3M | -$11.1M | -$13.2M |
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |